

LETTER TO THE EDITOR

Open Access

# Highly aggressive pathology of non-functional parathyroid carcinoma

Doina Piciu<sup>1,2\*</sup>, Alexandru Irimie<sup>2</sup>, George Kontogeorgos<sup>3</sup>, Andra Piciu<sup>4</sup> and Rares Buiga<sup>5</sup>

## Abstract

Parathyroid carcinoma is a rare malignant endocrine tumor accounting for only 0.5% to 5% of all primary hyperparathyroidism. Among these malignancies, only 10-25% are nonfunctioning. After the review of the literature we could only ascertain a number of 25 cases reported worldwide, since 1929, our case being the 26th, but the first with a very aggressive pathology, treated with chemotherapy scheme usually used for neuroendocrine tumors. Considering these facts, every single case presented is a step forward in defying the clinical presentation, for the awareness of the clinicians, and also in establishing standard adjuvant therapies.

**Keywords:** Parathyroid, Cancer, Non-functional

## Letters to the Editor

Parathyroid carcinoma is one of the very rare malignant endocrine tumors accounting for only 0.5% to 5% of all primary hyperparathyroidism [1]. Among these malignancies, only 10-25% are nonfunctioning [2], with normal values of parathyroid hormone (PTH). The difficulties in diagnosing these tumors rise not only because of the absence of symptoms of hyperparathyroidism, but also because of the hardship of the positive pathologic diagnosis [1-4].

After the review of literature we could only ascertain a number of 25 cases reported worldwide, since 1929 [5-31]. The present case is the 26th, being the first with a very aggressive pathology, treated with chemotherapy scheme usually used in the therapy of neuroendocrine tumors.

We present the case of a 51-years-woman referred for an indolent cervical mass measuring 2.5 cm in the right supraclavicular area with slight evolution during the last five years. Cervical ultrasound revealed a hypoechogenic nodule located in the lower part of the right thyroid lobe, without any other lesions worth being mentioned. The serum hormones were


found in normal range, as follows: thyroid stimulating hormone (TSH) was 1.21 mIU/L (N.V. 0.2-4.2 mIU/L); free-thyroxin (FT4) was 14.4 pmol/L (N.V. 12–22 pmol/L); calcium 9.1 mg/dL (N.V. 8.6-10.2 mg/dL); PTH was 54 ng/L (N.V.15-65 ng/L) and the anti-thyroid peroxidase antibodies (Anti-TPO) were negatives. Chromogranin A (Cg A) was 38 µg/L (N.V. 27–94 µg/L) and 5-hydroxyindolacetic acid (5-HIAA) was 4.2 mg/24 hours (N.V. 2–9 mg/24 hours). We performed the fine needle aspiration biopsy (FNAB) and a 2 ml volume of clear liquid was extracted, the cytology showing only colloid and amorphous material. Three years later, the patient was readmitted with a recurrence of the mass, located in the same area. The computed tomography scan (CT Scan) showed a nodule of 1 cm located in the lower part of the right thyroid lobe and another 2 cm tumor located near the thyroid gland, adherent to it and with close connection with the jugular vein (Figure 1). At this presentation, the serologic parameters were also in normal ranges. It was decided the total thyroidectomy, right selective lymphadenectomy and the radical resection of the tumor, of the jugular vein and of a part of the adjacent muscle. On Hematoxylin and Eosin (H&E) staining the tumor was composed of clear, partially oxyphil cells, showing atypia and nuclear pleomorphism with increased mitotic activity (Figure 2). At the periphery of the tumor a remnant of non-tumoral parathyroid tissue was still visible,

\* Correspondence: doina.piciu@gmail.com

<sup>1</sup>Department of Nuclear Medicine and Endocrine Tumours, Ion Chiricuță Institute of Oncology, 34-36, Republicii St, 400015, Cluj-Napoca, România

<sup>2</sup>Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca 400023, România

Full list of author information is available at the end of the article




**Figure 1** Pre-operative computed tomography of non-functional parathyroid carcinoma (arrowhead) displacing the trachea and the jugular vein, in the right anterior cervical area.

with compression changes. The rest of the resected thyroid gland presented the microscopy of a nodular goiter, without any signs of malignancy; all the lymph nodes resected were disease free.


The tumor cells presented the following immunohistochemical (IHC) profile: cytokeratin AE1/AE3 intensely positive; cytokeratin 7 antibody (CK7) focally positive; neuron specific enolase (NSE) intensely positive; Chromogranin A focally positive; gross cystic disease fluid protein (GCDPF15) focally positive in rare, isolated cells; progesterone receptor (PR)

weakly positive (1%); estrogen receptor (ER) negative; cytokeratin 20 antibody (CK20) negative; Thyroglobulin negative; Calcitonin negative; Synaptophysin negative; Neural cell adhesion molecules (CD56) negative; Mammaglobin negative; proliferating index (Ki67) staining (Figure 3) showed a high proliferative index (70%).


The histopathological diagnosis was probably of right parathyroid carcinoma; the normal levels of PTH and calcium enforced the PTH staining. Due to the impossibility of performing the analysis in the Institute, the accurate diagnosis was not set at that time and the block was sent for a second opinion in a national center, results showing that the PTH was negative. The confusing results misled the clinicians and made them unable to decide the treatment strategy. The capsular invasion and the infiltration of the adjacent muscle represented criteria for radiotherapy as adjuvant therapy; but the primary diagnostic of possible neuroendocrine tumor, with lack of response to external beam radiation and the presence of vascular emboli with high Ki-67 proliferation index (70%) were arguments for the chemotherapy scheme. The clinicians decided to start the chemotherapy cycles as indicated for the neuroendocrine tumors: Etoposide (Vepesid, VP16) 120 mg/sqm day 1–3 and Carboplatin AUC 5 =450 mg/day (VP16 + Carbo). A third histopathological report was demanded to the experts in Athens, Greece. Their findings indicated that PTH was extensively positive (Figure 4) and the final diagnosis was of non-functional parathyroid carcinoma. With this result, after 4 cycles of chemotherapy, the systemic treatment was discontinued. The replacement thyroid hormone therapy with 100 micrograms Levo-thyroxine daily was started and



**Figure 2** HE, 400x: Detail of nuclear atypia and multiple mitotic figures, with an atypical one in the center of the image.



**Figure 3** Ki67, 100x: Ki67 immunostaining, demonstrating a high proliferation index in the tumor.



**Figure 4** PTH, 100x: Tumor showing positive PTH immunostaining.

2 months after surgery the TSH and FT4 were in normal ranges. The follow-up was carried on every 3 months and consisted in determination of the TSH and FT4, PTH, calcium and cervical CT Scan, chest CT Scan and abdominal MRI. All the examinations were constantly normal (Figure 5). The latest check-up was performed at 15 months after surgery and showed no relapse and the highly aggressive pathology did not express an aggressive clinical behavior.

In our study, the lack of reference on this pathology led the clinicians to establish a chemotherapy protocol (VP16+ Carbo), used for the first time in the context of this condition.



**Figure 5** Computed tomography of the neck region, one year after therapy (surgery and chemotherapy); no local recurrence or regional metastases.

Non –functioning parathyroid carcinoma is an exceptionally rare malignancy, therefore any experience must be known, in order to improve its diagnostic and therapy.

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

DP has made substantial contributions to conception, acquisition, analysis and interpretation of data. AI performed the surgical procedures and participated in the design of the study. GK carried out the immunohistochemical studies and has been involved in revising the manuscript. AP elaborated the main document of the manuscript. RB carried out the pathological studies, and has given final approval of the version to be published. All authors read and approved the final manuscript.

#### Author details

<sup>1</sup>Department of Nuclear Medicine and Endocrine Tumours, Ion Chiricuță Institute of Oncology, 34-36, Republicii St, 400015, Cluj-Napoca, România. <sup>2</sup>Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca 400023, România. <sup>3</sup>Department of Pathology Athens, G. Gennimatas General Hospital, Athens, Greece. <sup>4</sup>Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca 400023, România. <sup>5</sup>Department of Pathology, Ion Chiricuță Institute of Oncology, Cluj-Napoca 400015, România.

Received: 23 May 2013 Accepted: 1 August 2013

Published: 3 August 2013

#### References

1. Talat N, Schulte K: Clinical presentation, staging and long-term evolution of parathyroid cancer. *Ann Surg Oncol* 2010, **17**:2156–2174.
2. Giessler GA, Beech DJ: Nonfunctional parathyroid carcinoma. *JNMA* 2001, **93**:251–255.
3. Wilkins BJ, Lewis J, James S: Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. *Head and Neck Pathol* 2009, **3**:140–149.
4. Bondeson L, Grimelius L, Delellis RA: Parathyroid carcinoma. In *World Health Organisation classification of tumours, pathology and*

- genetics: tumour of endocrine organs. Edited by Delellis RA. Lyon: IARC Press; 2004:124–133.
5. Guy CC: Tumors of the parathyroid glands. *Surg Gynecol Obstet* 1929, **149**:522–527.
  6. McQuillan AS: Parathyroid tumor: report of two cases. *Ann Surg* 1938, **108**:464–468.
  7. Armstrong HG: Primary carcinoma of the parathyroid gland with report of a case. *Bull Acad Med Tor* 1938, **11**:105–110.
  8. Sieracki JC, Horn RC Jr: Nonfunctional carcinoma of the parathyroid. *Cancer* 1960, **13**:502–506.
  9. Pachter MR, Lattes R: Uncommon mediastinal tumors. Report of two parathyroid adenomas, one nonfunctional parathyroid carcinoma and one "bronchial-type-adenoma". *Dis Chest* 1963, **43**:519–528.
  10. Altenähr E, Saeger W: Light and electron microscopy of parathyroid carcinoma: report of three cases. *Virchows Arch A Pathol Anat* 1973, **360**:107–122. doi:10.1007/BF00543222.
  11. Chahinian AP, Holland JF, Nieburgs HE, et al: Metastatic nonfunctioning parathyroid carcinoma: ultrastructural evidence of secretory granules and response to chemotherapy. *Am J Med Sci* 1981, **282**:80–84.
  12. Aldinger KA, Hickey RC, Ibanez ML, et al: Parathyroid carcinoma: a clinical study of seven cases of functioning and two cases of nonfunctioning parathyroid cancer. *Cancer* 1982, **49**:388–397.
  13. Anderson BJ, Samaan NA, Vassilopoulou-Sellin R, et al: Parathyroid carcinoma: features and difficulties in diagnosis and management. *Surgery* 1983, **94**:906–915.
  14. Ordoñez NG, Ibanez ML, Samaan NA, et al: Immunoperoxidase study of uncommon parathyroid tumors. *Am J Surg Pathol* 1983, **7**:535–542.
  15. Yamashita H, Noguchi S, Nakayama I, et al: Light and electron microscopic study of nonfunctioning parathyroid carcinoma: report of a case with a review of the literature. *Acta Pathol Jpn* 1984, **34**:123–132.
  16. Merlano M, Conte P, Scarsi P, et al: Non-functioning parathyroid carcinoma: a case report. *Tumori* 1985, **71**:193–196.
  17. Collins FD, Warren MC, Palmer FJ, Rankin DR: Nonfunctioning parathyroid carcinoma: a case history. *J Surg Oncol* 1986, **31**:60–61.
  18. Murphy MN, Glennon PG, Diocee MS, et al: Nonsecretory parathyroid carcinoma of the mediastinum: light microscopic, immunocytochemical, and ultrastructural features of a case, and review of the literature. *Cancer* 1986, **58**:2468–2476.
  19. Klink B, Karulf R, Maimon W, Peoples J: Nonfunctioning parathyroid carcinoma. *Am Surg* 1991, **57**:463–467.
  20. Yamashita H, Noguchi S, Murakami N, Toda M, Adachi M, Daa T: Immunohistological study of nonfunctional parathyroid carcinoma. Report of a case. *Acta Pathol Jpn* 1992, **42**:279–285.
  21. Pelizzo MR, Piotto A, Bergamasco A, Rubello D, Casara D: Parathyroid carcinoma. Therapeutic strategies derived from 20 years of experience. *Minerva Endocrinol* 2001, **26**:23–29.
  22. Eurlings M, Frijns CJM, Jeurissen FJF: Painful ophthalmoplegia from metastatic nonproducing parathyroid carcinoma: case study and review of the literature. *Neuro Oncol* 2002, **4**:44–48.
  23. Kirkby-Bott J, Lewis P, Harmer CL, et al: One stage treatment of parathyroid carcinoma. *Eur J Surg Oncol* 2005, **31**:78–83.
  24. Ashkenazi D, Elmalah I, Rakover Y, Luboshitzky R: Concurrent nonfunctioning parathyroid carcinoma and parathyroid adenoma. *Am J Otolaryngol* 2006, **27**:204–206.
  25. Fernandez-Ranvier GG, Jensen K, Khanafshar E: Nonfunctioning parathyroid carcinoma: case report and review of the literature. *Endocr Pract* 2007, **13**:750–757.
  26. Gao WC, Ruan CP, Zhang JC, Liu HM, Xu XY, Sun YP, Wang Q: Nonfunctional parathyroid carcinoma. *J Cancer Res Clin Oncol* 2010, **136**:969–974.
  27. Nakamura Y, Kataoka H, Sakoda T, Horie Y, Kitano H: Nonfunctional parathyroid carcinoma. *Int J Clin Oncol* 2010, **15**:500–503.
  28. Krvavica A, Kovacic M, Baraka I, Rudic M: Non-functioning parathyroid gland carcinoma: case report. *Acta Clin Croat* 2011, **50**:233–237.
  29. Uchida N, Ishiguro K, Suda T, Horie Y, Nishimura M: Metastatic breast tumor due to nonfunctional parathyroid carcinoma. *Intl Canc Conf J* 2012, **1**:47–52.
  30. Kotromanovic Z, Birtic D, Vceva A: Non-functional parathyroid gland carcinoma. *Coll Antropol* 2012, **36**(Suppl. 2):23–25.
  31. Guo H, Mai R, Liu M, Peng H, Yang X, Wu M, Zhang G: Nonfunctional parathyroid carcinoma after breast carcinoma. *J Clin Oncol* 2013. [Epub ahead of print] PubMed PMID: 23341525.

doi:10.1186/1750-1172-8-115

**Cite this article as:** Piciu et al.: Highly aggressive pathology of non-functional parathyroid carcinoma. *Orphanet Journal of Rare Diseases* 2013 **8**:115.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

